Landmark Trial Pinpoints Which HER2-Positive Breast Cancers Respond to Shorter, Gentler Chemotherapy
Secondary results from the ECOG-ACRIN CompassHER2-pCR trial identify clinical and molecular factors, including HER2DX genomic scores, that predict which stage ...
